Sangamo Therapeutics 향후 성장

Future 기준 점검 5/6

Sangamo Therapeutics은 연간 수입과 매출이 각각 60.5%와 42.7% 증가할 것으로 예상되고 EPS는 연간 60.6%만큼 증가할 것으로 예상됩니다.

핵심 정보

60.5%

이익 성장률

60.55%

EPS 성장률

Biotechs 이익 성장	22.8%
매출 성장률	42.7%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	10 Feb 2026

최근 향후 성장 업데이트

Recent updates

Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Feb 03

Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive

Nov 23

There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise

Oct 07

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth

Sep 23

Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 24

Neurology IND And Fabry Agreements Will Transform Treatment

Apr 01 Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Mar 04

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%

Dec 08

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

Nov 20

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Oct 23

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?

Oct 21

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11

이익 및 매출 성장 예측

NasdaqCM:SGMO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	270	107	106	116	3
12/31/2027	165	16	21	31	3
12/31/2026	55	-78	-54	-44	4
12/31/2025	66	-81	-79	-77	4
9/30/2025	33	-109	-76	-76	N/A
6/30/2025	82	-63	-36	-36	N/A
3/31/2025	64	-79	-45	-45	N/A
12/31/2024	58	-98	-67	-67	N/A
9/30/2024	52	-135	-117	-114	N/A
6/30/2024	12	-248	-179	-173	N/A
3/31/2024	19	-328	-218	-207	N/A
12/31/2023	176	-258	-246	-225	N/A
9/30/2023	201	-250	-257	-231	N/A
6/30/2023	218	-199	-265	-238	N/A
3/31/2023	241	-127	-258	-231	N/A
12/31/2022	111	-192	-244	-224	N/A
9/30/2022	112	-178	-235	-219	N/A
6/30/2022	114	-172	-241	-225	N/A
3/31/2022	113	-176	-242	-224	N/A
12/31/2021	111	-178	-257	-233	N/A
9/30/2021	109	-181	-209	-185	N/A
6/30/2021	138	-135	-116	-92	N/A
3/31/2021	131	-124	101	120	N/A
12/31/2020	118	-121	155	170	N/A
9/30/2020	147	-76	136	153	N/A
6/30/2020	111	-102	64	81	N/A
3/31/2020	107	-96	-137	-118	N/A
12/31/2019	102	-95	-165	-144	N/A
9/30/2019	74	-118	-206	-164	N/A
6/30/2019	76	-104	N/A	-152	N/A
3/31/2019	80	-90	N/A	10	N/A
12/31/2018	84	-68	N/A	37	N/A
9/30/2018	71	-63	N/A	60	N/A
6/30/2018	59	-62	N/A	72	N/A
3/31/2018	46	-58	N/A	6	N/A
12/31/2017	37	-55	N/A	11	N/A
9/30/2017	32	-51	N/A	16	N/A
6/30/2017	23	-58	N/A	14	N/A
3/31/2017	19	-72	N/A	-59	N/A
12/31/2016	19	-72	N/A	-66	N/A
9/30/2016	20	-76	N/A	-63	N/A
6/30/2016	25	-66	N/A	-60	N/A
3/31/2016	30	-52	N/A	-52	N/A
12/31/2015	40	-41	N/A	-34	N/A
9/30/2015	45	-31	N/A	-27	N/A
6/30/2015	49	-29	N/A	-19	N/A
3/31/2015	51	-24	N/A	-19	N/A

애널리스트 향후 성장 전망

수입 대 저축률: SGMO 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: SGMO (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: SGMO 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: SGMO 의 수익(연간 42.7%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: SGMO 의 수익(연간 42.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SGMO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/15 17:13
종가	2026/03/13 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서 생성에 사용된 분석 모델의 세부 정보는 저희 Github 페이지에서 확인하실 수 있으며, 보고서 사용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sangamo Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Gregory Harrison	BofA Global Research
Douglas Buchanan	Brean Capital Historical (Janney Montgomery)
John Newman	Citizens JMP Securities, LLC

Sangamo Therapeutics 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Forecast to breakeven in 2027

Consensus revenue estimates fall by 37%

Price target decreased by 21% to US$3.25

Consensus revenue estimates fall by 54%

Price target decreased by 21% to US$4.10

Consensus revenue estimates fall by 17%

Recent updates

Sangamo Therapeutics, Inc. Advances Rolling Submission Of BLA To U.S. FDA For ST-920 In Fabry Disease

Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million.

Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

New major risk - Share price stability

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Forecast to breakeven in 2027

Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive

Sangamo Therapeutics, Inc. Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Consensus revenue estimates fall by 37%

Price target decreased by 21% to US$3.25

Third quarter 2025 earnings released: US$0.12 loss per share (vs US$0.045 profit in 3Q 2024)

Sangamo Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Nasdaq Grants 180 Day Extension to Sangamo Therapeutics, Inc. to Regain Compliance

There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth

Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

New major risk - Shareholder dilution

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Sangamo Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%

New minor risk - Market cap size

Consensus revenue estimates fall by 54%

New major risk - Share price stability

Price target decreased by 21% to US$4.10

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million.

Sangamo Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

New major risk - Financial position

Neurology IND And Fabry Agreements Will Transform Treatment

Full year 2024 earnings: EPS and revenues miss analyst expectations

Sangamo Therapeutics, Inc. to Report Q4, 2024 Results on Mar 17, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 17%

Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?

Consensus revenue estimates increase by 32%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New major risk - Share price stability

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

Consensus EPS estimates fall by 10%

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

New major risk - Financial position

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024

Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.

Consensus revenue estimates fall by 13%

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023